Verrica Pharmaceuticals Inc.VRCANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank11
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P11
Within normal range
vs 5Y Ago
-16.4x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-25.21%
2024-41.66%
202366.38%
2022-23.42%
20211.63%
20201.54%
201920.35%
2018243.86%
2017118.26%
20160.00%